Alembic Pharmaceuticals Ltd.

₹816.4

-1 (-0.1%)

APLLTD Share Price

Pharmaceuticals & Biotechnology

As on September 10, 2026

SectorHealthcare

IndustryPharmaceuticals & Biotechnology

Basic IndustryPharmaceuticals

Market Cap₹ 16,100 Cr

P/E Ratio23.78

Dividend Yield0.73 %

Trendline Performance

We are partnered with TradingView, a global leader in charting and market analysis. Access real-time stock data, explore the powerful Stock Screener , and uncover insights with multiple tools designed for traders.

Unlock Stock of the Month

T&C*

Technicals

Indicators	Value	Signal
5-DMA	810.01	Bullish
10-DMA	817.28	Bearish
20-DMA	818.66	Bearish
50-DMA	821.3	Bearish
100-DMA	791.24	Bullish
200-DMA	787.22	Bullish

Historical Performance

1 Year

-14.2%

3 Years

6.8%

5 Years

6.6%

10 Years

28.7%

Shareholding Pattern

Values Analysis

Loading chart...

Profit & Loss

Below figures are in Rs. Crores

Particulars	Mar-2026	Mar-2025	Mar-2024	Mar-2023	Mar-2022
Net Sales	73,449	66,721	62,286	56,526	53,058
Total Expenditure	62,269	56,692	52,960	49,446	44,316
Other Income	549	479	290	30	505
Operating Profit	11,729	10,508	9,617	7,111	9,246
Interest	936	788	562	502	177
Depreciation	3,185	2,786	2,727	2,754	2,868
Profit Before Tax	6,940	7,072	6,318	3,546	6,254
Consolidated Net Profit	6,748	5,834	6,158	3,420	5,209
Adjusted EPS	34	30	31	17	27

Compounded Sales Growth

10 Years:18.3

5 Years:6.4

3 Years:5.4

TTM:1.9

Compounded Profit Growth

10 Years:-1.3

5 Years:-10.1

3 Years:14.6

TTM:3

Stock Price CAGR

10 Years:2.6

5 Years:1.3

3 Years:2.2

TTM:-13.8

Return on Equity

10 Years:21.4

5 Years:26.5

3 Years:31.3

last year:34.3

Quarterly Results

Below figures are in Rs. Crores

Particulars	Sep-2024	Dec-2024	Mar-2025	Jul-2025	Sep-2025
Sales	1,70,754	1,35,936	1,28,552	1,22,189	1,05,161
Expenses	63,042	56,557	52,457	45,459	34,856
Operating Profit	1,07,712	79,379	76,096	76,730	70,304
OPM %	63%	58%	59%	63%	67%
Other Income	33,912	31,759	27,333	24,879	18,947
Interest	77,780	58,584	59,248	62,137	53,713
Depreciation	2,345	1,681	1,385	1,277	1,221
Profit Before Tax	61,498	50,873	42,796	38,195	34,318
Tax %	25%	25%	26%	29%	35%
Net Profit	46,149	38,151	31,857	27,296	22,446
EPS in Rs	83	69	58	50	42

Balance Sheet

Below figures are in Rs. Crores

Particulars	Mar-2026	Mar-2025	Mar-2024	Mar-2023	Mar-2022
Share Capital	393	393	393	393	393
Total Reserves	56,355	51,516	47,789	43,312	51,982
Long-Term Borrowings	---	---	---	---	---
Total Non-Current Liabilities	2,302	51	28	524	1,621
Other Current Liabilities	3,940	2,321	2,237	2,512	5,165
Short Term Borrowings	12,186	11,956	4,305	6,359	4,300
Total Liabilities	85,860	77,088	63,412	60,637	72,302
Capital Work in Progress	6,337	8,372	5,244	6,013	22,058
Long Term Loans & Advances	154	311	333	537	349
Currents Investments	---	---	---	---	---
Short Term Loans and Advances	3,752	3,425	2,890	2,546	4,369
Total Current Assets	46,356	41,897	31,438	29,139	29,748
Total Assets	85,860	77,088	63,412	60,637	72,302
Adjusted Book Value	289	264	245	222	266

Positive

(80 to 100)

Neutral

(60 to 79)

Negative

(0 to 59)

The stock has a moderate PE of 23.78, suggesting fair valuation relative to earnings.
Over the last three years, the stock delivered a weak 3-year price CAGR of 2.2%, indicating poor shareholder returns.
The stock carries a beta of 0.9, indicating volatility broadly in line with the market.
In the last financial year, the company reported an EBITDA of ₹11729 million, reflecting positive operating performance.
In the previous financial year, the company generated revenue of ₹73449 million, indicating a large and established business.

Investment Calculator

Investment Amount:₹

Investment Amount: ₹ 1000000

Current Value: ₹ 861954.3

No. of Shares: 1056 (Approx)

Performance:-13.8%

-138045.7

NIFTY Performance: -6.1%

1 day Top Gainers